X-ray manufacturer Del Global Technologies posted what it calls the strongest fourth-quarter and fiscal-year results in its history. These 1998 figures are the result of a combination of internal revenue growth and a strong outsourcing trend by global
X-ray manufacturer Del Global Technologies posted what it calls the strongest fourth-quarter and fiscal-year results in its history. These 1998 figures are the result of a combination of internal revenue growth and a strong outsourcing trend by global medical equipment manufacturers.
For the year (end-August), Del reported net sales of $62.3 million, a 14% increase from the $54.7 million the company posted in 1997. Net income was $5.8 million, compared with the previous years $4.9 million.
Dels fourth-quarter revenues were also strong at $17.7 million, up 15% from $15.4 million in the fourth quarter of 1997. Net income for the period was $1.7 million, compared with $1.5 million the year before.
Medical imaging sales now contribute 80% of the Valhalla, NY, companys revenues, according to chief executive Leonard Trugman. The companys backlog stood at $36 million at year end.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.